leflunomide

Leflunomide (HWA486) is an immunomodulatory agent used in the therapy of rheumatoid arthritis and psoriatic arthritis.

Leflunomide-d4 is a deuterated compound of Leflunomide. Leflunomide has a CAS number of 75706-12-6. Leflunomide is an immunomodulatory agent used in the therapy of rheumatoid arthritis and psoriatic arthritis.

Leflunomide EP Impurity B-d4 is a deuterated compound of Leflunomide EP Impurity B. Leflunomide EP Impurity B has a CAS number of 163451-81-8. Teriflunomide is the principal active metabolite of leflunomide, an approved therapy for rheumatoid arthritis and multiple sclerosis.

Teriflunomide (A 77-1726) is the principal active metabolite of leflunomide, an approved therapy for rheumatoid arthritis and multiple sclerosis.

DHODH-IN-12 is a leflunomide derivative and a weak dihydrorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.07.

DHODH-IN-11 is a leflunomide derivative and weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.03.

PfDHODH-IN-1, an analogue of the active Leflunomide metabolite, exhibits antimalarial activity.

X 910279 is a leflunomide analog and a malononitrilamide.

Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 μM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor. Laflunimus is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH).

hDHODH-IN-2, an analogue of the active metabolite of Leflunomide, is a human dihydroorotate dehydrogenase (hDHODH) inhibitor with anti-inflammatory activity.